AVR 0.99% $15.30 anteris technologies ltd

Ann: Annual Report to shareholders, page-58

  1. 3,092 Posts.
    lightbulb Created with Sketch. 69
    I think we could see a doubling or slightly better on the prior corresponding period.

    Wayne said in the webinar that ADAPT sales were 100% higher in The US for July of 2017 than July of 2016... The Saint spoke of a 'breakout' across the whole ADAPT range after his first month at Admedus.... Strong compounding growth for VascuCel and Neo.... And a few sales of CardioCel3D to the 10 'super clinics' which have been given the privilege of trialing it.

    September quarter for 2016 was $1.6 million from memory, I'm calling $3.3 million in ADAPT sales for the September quarter of 2017.

    If my figure is close to correct it is proof and confirmation that The ADAPT Tidal Wave has begun!
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.